Equibles does not estimate personal net worth.
Get an email with a short summary when Harmony Biosciences Holdings, Inc. publishes a filing, an earnings call transcript or a press release.
Get HRMY alertsJeffrey Dayno is recorded as CEO at Harmony Biosciences Holdings, Inc. (HRMY). The newest filing on record that lists Jeffrey Dayno as CEO at Harmony Biosciences Holdings, Inc. (HRMY) is dated April 4, 2025. The proxy statement of Harmony Biosciences Holdings, Inc. reports total compensation of $7,145,170 for Jeffrey Dayno in fiscal 2024, including a base salary of $715,000. Disclosed compensation is on record for 6 fiscal years. Jeffrey Dayno has spoken on 11 earnings calls across 1 company, most recently for Harmony Biosciences Holdings, Inc. on November 4, 2025. Harmony Biosciences Holdings, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Harmony Biosciences Holdings, Inc. includes Jeffrey M. Dayno (CEO and Board Member), Peter Anastasiou (CEO, COO and Board Member), Jeffrey S. Aronin (Chairman) and 7 others.
“I want to start off by saying how proud I am of the Harmony team and their exceptional performance this quarter. It reaffirms Harmony's reputation for executional excellence.”
“I want to begin today's call by reaffirming something we believe is becoming incredibly clear. We have built something rare in our industry, a profitable, self-funding biotech company with an innovative late-stage pipeline poised to deliver meaningful value for both patients and shareholders.”
“Before we get started, I am very excited to introduce and welcome Adam Zaeske, our new Chief Commercial Officer, to the Harmony team. Adam will be sharing a bit about his background in a moment, but let me tell you, in just six weeks at Harmony, he has already made a big impact.”
“2024 was a year of strong execution and meaningful progress for Harmony Biosciences. We continue to strengthen our leadership position in Sleep/Wake while advancing and expanding one of the most robust late-stage CNS pipelines in the industry.”
“Q3 was another quarter of strong momentum for the team at Harmony, driving significant revenue growth for WAKIX and advancing our late-stage clinical development programs.”
Start not stated–present
Last confirmed April 4, 2025
Proxy statement
Start not stated–2022-04-08
Last confirmed by a filing; no departure on record
Biotechnology · Healthcare
CEO
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2024 | Harmony Biosciences Holdings, Inc. (HRMY) | President and Chief Executive Officer | $715,000 | $7,145,170 |
| 2023 | Harmony Biosciences Holdings, Inc. (HRMY) | President and Chief Executive Officer | $612,500 | $4,450,294 |
| 2022 | Harmony Biosciences Holdings, Inc. (HRMY) | President and Chief Executive Officer | $458,993 | $762,152 |
| 2021 | Harmony Biosciences Holdings, Inc. (HRMY) | Chief Medical Officer | $445,624 | $702,744 |
| 2020 | Harmony Biosciences Holdings, Inc. (HRMY) | Chief Medical Officer | $431,388 | $2,702,943 |
| 2019 | Harmony Biosciences Holdings, Inc. (HRMY) | EVP and Chief Medical Officer | $414,000 | $672,175 |
